These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39235485)

  • 1. Innovation at the Interface between Academia and Industry: The BioMed X Model.
    Cristian FB; Tidona C; Rückle T
    Handb Exp Pharmacol; 2024 Sep; ():. PubMed ID: 39235485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines, editors, pharma and the biological paradigm shift.
    Singh AR; Singh SA
    Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The connection between academia and industry.
    Singh A; Singh S
    Mens Sana Monogr; 2005 Mar; 3(1):5-35. PubMed ID: 22679346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational precision medicine: an industry perspective.
    Hartl D; de Luca V; Kostikova A; Laramie J; Kennedy S; Ferrero E; Siegel R; Fink M; Ahmed S; Millholland J; Schuhmacher A; Hinder M; Piali L; Roth A
    J Transl Med; 2021 Jun; 19(1):245. PubMed ID: 34090480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open innovation: A paradigm shift in pharma R&D?
    Schuhmacher A; Gassmann O; Bieniok D; Hinder M; Hartl D
    Drug Discov Today; 2022 Sep; 27(9):2395-2405. PubMed ID: 35643258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collective intelligence for translational medicine: Crowdsourcing insights and innovation from an interdisciplinary biomedical research community.
    Budge EJ; Tsoti SM; Howgate DJ; Sivakumar S; Jalali M
    Ann Med; 2015; 47(7):570-5. PubMed ID: 26469375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging Industry-Academia Collaborations in Adaptive Biomedical Innovation.
    Stewart SR; Barone PW; Bellisario A; Cooney CL; Sharp PA; Sinskey AJ; Natesan S; Springs SL
    Clin Pharmacol Ther; 2016 Dec; 100(6):647-653. PubMed ID: 27617845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
    Chung TD
    Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rules of engagement: Promoting academic-industry partnership in the era of digital pathology and artificial intelligence.
    Pantanowitz L; Bui MM; Chauhan C; ElGabry E; Hassell L; Li Z; Parwani AV; Salama ME; Sebastian MM; Tulman D; Vepa S; Becich MJ
    Acad Pathol; 2022; 9(1):100026. PubMed ID: 35669406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thoughts of the combination of medicine and engineering and collaborative innovation on surgery in China].
    Lyu ZJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jun; 23(6):562-565. PubMed ID: 32521975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partnerships in Pharma--An Economist Intelligence Unit Seminar--Building Innovation into Alliances and Business Models. 1 October 2010, London, UK.
    Kibble A
    IDrugs; 2010 Dec; 13(12):813-5. PubMed ID: 21154130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
    Povsic TJ; Scott R; Mahaffey KW; Blaustein R; Edelberg JM; Lefkowitz MP; Solomon SD; Fox JC; Healy KE; Khakoo AY; Losordo DW; Malik FI; Monia BP; Montgomery RL; Riesmeyer J; Schwartz GG; Zelenkofske SL; Wu JC; Wasserman SM; Roe MT
    Cardiovasc Drugs Ther; 2017 Aug; 31(4):445-458. PubMed ID: 28735360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crowdsourcing and open innovation in drug discovery: recent contributions and future directions.
    Thompson DC; Bentzien J
    Drug Discov Today; 2020 Dec; 25(12):2284-2293. PubMed ID: 33011343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open innovation in early drug discovery: roadmaps and roadblocks.
    Reichman M; Simpson PB
    Drug Discov Today; 2016 May; 21(5):779-88. PubMed ID: 26743597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Industry-Academic Relationship in a New Era of Drug Discovery.
    Vallance P
    J Clin Oncol; 2016 Oct; 34(29):3570-3575. PubMed ID: 27458309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
    Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
    Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of industry-university-research collaboration and convergence on economic development: Evidence from chengdu-chongqing economic circle in China.
    Xiao H; Cui X; Sarker MNI; Firdaus RBR
    Heliyon; 2023 Nov; 9(11):e21082. PubMed ID: 37920487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helping science and drug development to succeed through pharma-academia partnerships: Yale Healthcare Conference 2013.
    Yang DX; Kim YA
    Yale J Biol Med; 2013 Sep; 86(3):429-32. PubMed ID: 24058318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.